NCT06312683View on ClinicalTrials.gov

Rifaximin for the Secondary Prevention of Recurrent Pouchitis

PHASE4RecruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
Pouchitis
Interventions
DRUG

Rifaximin 550 MG Oral Tablet [XIFAXAN]

Rifaximin 550 MG Oral Tablet \[XIFAXAN\] Taken twice a day for up to 365 days

Trial Locations (2)

10016

RECRUITING

NYU IBD Center, New York

27599

RECRUITING

University of North Carolina, Chapel Hill

All Listed Sponsors
collaborator

Bausch Health Americas, Inc.

INDUSTRY

lead

University of North Carolina, Chapel Hill

OTHER

NCT06312683 - Rifaximin for the Secondary Prevention of Recurrent Pouchitis | Biotech Hunter | Biotech Hunter